← Back to Clinical Trials
Recruiting NCT06982794

NCT06982794 A Patient-Directed Mobile Tool to Streamline the QoL Assessment and Monitoring in Urothelial Carcinoma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06982794
Status Recruiting
Phase
Sponsor IRCCS San Raffaele
Condition Urothelial Carcinoma (UC)
Study Type OBSERVATIONAL
Enrollment 50 participants
Start Date 2025-06-30
Primary Completion 2025-09-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 50 participants in total. It began in 2025-06-30 with a primary completion date of 2025-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to select contents and tools for the future development of a web app aiming to support patients' navigation for empowering decision-making through a higher awareness of urothelial carcinoma and its treatments, improving also educational aspects. The main question it aims to answer is: What are the contents that patients diagnosed with urothelial carcinoma find useful to include in a web app to streamline their quality of life assessment and monitoring? Participants candidate for systemic treatments, or already under treatment, will answer questionnaires about the tools to include in a web app designed for urothelial carcinoma.

Eligibility Criteria

Inclusion Criteria: * histological diagnosis of urothelial carcinoma; * ≥ 18 years old, * candidate for systemic treatment with chemotherapy, immune-checkpoint inhibitors, antibody-drug conjugates, or target therapy (patients can be enrolled also if the treatment has started), * possession of a mobile device (e.g., smartphone or personal computer) with the physical and psychological ability to use mobile devices, * understanding and speaking the Italian language, * ability to sign an informed consent. Exclusion Criteria: * not possession of a mobile device, * unwillingness to give informed consent.

Frequently Asked Questions

Who can join the NCT06982794 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Urothelial Carcinoma (UC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06982794 currently recruiting?

Yes, NCT06982794 is actively recruiting participants. Visit ClinicalTrials.gov or contact IRCCS San Raffaele to inquire about joining.

Where is the NCT06982794 trial being conducted?

This trial is being conducted at Milan, Italy.

Who is sponsoring the NCT06982794 clinical trial?

NCT06982794 is sponsored by IRCCS San Raffaele. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology